Phase II trial of Didemnin B in patients with advanced renal cell carcinoma Journal Article

  


Authors: Motzer, R.; Scher, H.; Bajorin, D.; Sternberg, C.; Bosl, G. J.
Article Title: Phase II trial of Didemnin B in patients with advanced renal cell carcinoma
Abstract: Twenty-three patients with advanced renal cell cancer were treated with Didemnin B. One partial response was achieved (5%) in 21 evaluable patients. An allergic reaction was noted in four patients including one patient with anaphylaxis. Didemnin B is not recommended in the treatment of renal cell carcinoma. © 1990 Kluwer Academic Publishers.
Keywords: adult; aged; liver toxicity; allergy; nausea; vomiting; renal cell carcinoma; kidney neoplasms; carcinoma, renal cell; kidney cancer; drugs, investigational; antibiotics, antineoplastic; peptides, cyclic; intravenous drug administration; middle age; drug evaluation; human; male; female; priority journal; article; support, u.s. gov't, p.h.s.; didemnin b
Journal Title: Investigational New Drugs
Volume: 8
Issue: 4
ISSN: 0167-6997
Publisher: Springer  
Date Published: 1990-11-01
Start Page: 391
End Page: 392
Language: English
DOI: 10.1007/bf00198598
PUBMED: 2084073
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025077132&doi=10.1007%2fBF00198598&partnerID=40&md5=231d289acfd9f47158f7372cd78eb1a3
Notes: Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Dean Bajorin
    660 Bajorin
  2. Robert Motzer
    1247 Motzer
  3. Howard Scher
    1130 Scher
  4. George Bosl
    430 Bosl
  5. Cora N. Sternberg
    36 Sternberg
Related MSK Work